PTC Therapeutics

Historical price data

PTC Therapeutics is a patient-centric, publicly traded biopharma leader dedicated to translating groundbreaking science into life-changing treatments for rare diseases. Its key achievements include commercializing a series of 'firsts' in rare disease treatment and building a diversified pipeline targeting neurological and metabolic disorders. The company's strategic direction is fueled by its deep expertise in two core scientific platforms—splicing modifiers and inflammation/ferroptosis inhibitors—and a robust global commercial infrastructure to support its mission of delivering transformative medicines worldwide.

PTC's core technology is based on two proprietary platforms: 1) RNA splicing modifiers, which use small molecules to modulate protein production by affecting mRNA processing, and 2) Inflammation & Ferroptosis targeting, which focuses on pathways involving oxidative stress and a specific form of cell death.

63 drugs in pipeline, 21 in Phase 3

Total raised: $252M

PTC faces competition from large biopharma and specialized rare disease companies, including Sarepta and Pfizer in DMD, Biogen and Novartis in SMA, and Larimar in Friedreich's ataxia. Its differentiation stems from its novel platform technologies (splicing/ferroptosis), expertise in CNS delivery, and integrated global commercial operations.